Objective: To compare the efficacy and safety of scheduled lowdose haloperidol versus placebo for the prevention of delirium (Intensive Care Delirium Screening Checklist ≥ 4) administered to critically ill adults with subsyndromal delirium (Intensive Care Delirium Screening Checklist = 1-3).
outcome-predicting spectrum of delirium symptoms and is present when the Intensive Care Delirium Screening Checklist (ICDSC) score is 1-3 out of 8 (4, 5) . A critically ill patient who develops subsyndromal delirium, compared with one who develops neither delirium (ICDSC ≥ 4) nor subsyndromal delirium, is more likely to die in the ICU, spend more time hospitalized, and to be discharged to a long-term care facility rather than home (4) .
Recent Society of Critical Care Medicine (SCCM) practice guidelines strongly advocate the use of nonpharmacologic strategies such as early mobilization and daily sedation interruption to prevent delirium in critically ill adults (6) (7) (8) . However, a recommendation regarding the use of a pharmacologic delirium prevention strategy (e.g., dexmedetomidine, antipsychotic therapy) was not made since no published evidence clearly demonstrates the benefit of such an intervention in critically ill adults (6) (7) (8) (9) . Medications can easily be administered in the ICU, and thus, critical care clinicians are interested in the use of any pharmacologic intervention(s) that might provide added benefit to that which is observed with the use of nonpharmacologic delirium prevention interventions alone.
Perioperative use of low-dose antipsychotic therapy in noncritically ill patients undergoing elective major surgery, where a short postoperative ICU admission is sometimes required, has been shown to reduce delirium burden (i.e., delirium occurence, duration, or both) (10) (11) (12) (13) (14) (15) (16) . However, the results of these investigations cannot be extrapolated to the critically ill given the different mechanisms, risk factors, and outcomes of delirium that exist between the ICU and non-ICU populations (9, 17, 18) .
Antipsychotic administration in the ICU is controversial (9, (19) (20) (21) and has not been studied in critically ill patients with subsyndromal delirium. One single-center, uncontrolled, before-after analysis suggested that the administration of haloperidol throughout the period of critical illness may reduce delirium and lower mortality (19) . However, the results from two randomized, placebo-controlled studies in critically ill adults, where nearly half the patients in each study were delirium free at the time of randomization, suggest that administration of haloperidol throughout the ICU stay will not reduce days spent with delirium or coma or alter clinically meaningful outcomes, such as delirium duration, time on mechanical ventilation, or post-ICU disposition (20, 21) . Since the role of haloperidol as a strategy to prevent delirium in critically ill adults remained unclear, we sought to test the hypothesis that the administration of IV haloperidol to mechanically ventilated, critically ill adults patients with subsyndromal delirium would prevent conversion to delirium.
METHODS

Setting
This randomized, double-blind, placebo-controlled trial was conducted, in three 10-bed ICUs at Tufts Medical Center, a 320-bed academic medical center located in Boston, MA. Each of the three ICUs (two medical and one surgical) were closed units and had the same well-established pain, sedation, and delirium assessment practices. Pain was evaluated at least every 4 hours and treated when present. Level of sedation was evaluated at least every 4 hours using the Sedation Agitation Scale (SAS), and sedative therapy was titrated to maintain patients at a lightly sedated state (SAS = 3). Choice of analgesic and sedative therapy was left to the discretion of the bedside clinician. All patients were managed with the same daily awakening (DA)-spontaneous breathing trial (SBT) protocol (22) . A delirium screening protocol, in place in all three units for more than a decade, that clinicians received regular educational updates regarding and that had been used in multiple controlled ICU studies, mandated the evaluation of all ICU patients for the presence of delirium by the bedside nurse each shift using the ICDSC (Supplemental Appendix, Supplemental Digital Content 1, http://links.lww.com/CCM/B510) (5, (23) (24) (25) . If the patient is deeply sedated (SAS = 2) or in coma (SAS = 1), the protocol advocates that no ICDSC assessment be performed (and the ICDSC is considered negative by default) until wakefulness is achieved with DA and the patient reaches a SAS of at least 3 (5, 26) .
Patients
At the time of ICU admission, and on a daily basis for up to 3 days, the daily sedation and cognitive status of consecutive mechanically ventilated patients admitted to any of the three study ICUs and expected by the ICU team to have an ICU admission at least 24 hours was categorized by the investigative team (based on the SAS and ICDSC assessments documented by the bedside nurse over the prior 24 hr) as having: 1) persistent deep sedation or coma, 2) delirium, 3) subsyndromal delirium, or 4) neither delirium nor subsyndromal delirium. The presence of delirium precluded further consideration of a patient for the study. If subsyndromal delirium was present, and an additional ICDSC evaluation by a member of the investigative team confirmed its presence, the patient was considered eligible and screened for study exclusion criteria ( Table 1) . In general, patients were excluded from the study if they were deemed to be at greater risk for experiencing a haloperidolassociated safety concerns (e.g., age ≥ 85 yr, severe dementia) or had a condition that might preclude delirium evaluation (e.g., ICU admission because of an acute neurologic injury). Given a concern that any beneficial effect of a pharmacologic delirium prevention intervention could wane over the course of the ICU stay, patients admitted in the ICU for 4 or more days were excluded from the study. The Tufts Medical Center Institutional Review Board approved the study, and written informed consent was obtained from each subject's legally authorized representative prior to study randomization. treatment allocation known only to the investigational pharmacist. Haloperidol was chosen over other antipsychotic agents given its benefit in reducing delirium incidence or burden in patients undergoing major surgery and the fact that it can be administered IV (11, 12, 14) . Published data regarding the pharmacodynamic response of haloperidol in the critically ill do not exist. The daily dose of haloperidol used (4 mg) in the study was, therefore, based on the fact that this is a dose that has been used in other ICU clinical studies (19, 20) and, in non-ICU, nondelirium investigations have been shown to reliably occupy 60% of dopamine-2 receptors (27) . Each study dose was prepared by the investigational pharmacy so that an identical looking 0.5 mL tuberculin syringe contained 0.2 mL of either haloperidol 1 mg or 5% dextrose in water (D5W). Subjects, clinicians, and all study personnel were blinded to study drug assignment. Each dose of the study drug was administered by the bedside nurse as a slow IV push over 1 minute into a preexisting IV catheter and then flushed with 10 mL of D5W. Study medication was administered until one of the following occurred: delirium, ICU discharge, 10 days of therapy had elapsed, or an adverse effect necessitating study drug discontinuation.
The use of dexmedetomidine and off-study antipsychotic therapy was not allowed during the period of study drug administration unless medically necessary. All decisions regarding sedation and analgesia therapy and ventilator management were left to the discretion of the ICU team. All patients were managed with the same DA-SBT protocol (22) . An early mobilization protocol was implemented in one of the three study ICUs part-way through the study (8) .
Study Outcomes and Endpoints
All subjects were evaluated for the presence of delirium using the ICDSC-based protocol described above. A study investigator confirmed the presence of delirium by the bedside nurse using the ICDSC assessment; any disagreement was resolved through consensus. The presence of delirium was subsequently confirmed by a consultation psychiatrist using Diagnostic and Statistical Manual of Mental Disorders criteria (27) ; discordance between the psychiatric consultation and the bedside nurse and study investigator's ICDSC assessments were resolved through consensus.
At the time of enrollment, the following baseline demographics were collected: age, gender, severity of illness as estimated by both the Acute Physiology and Chronic Health Evaluation II (28) and Sequential Organ Failure Assessment score (29) , ICU type, number of days of ICU admission before study enrollment, location before both hospitalization and ICU admission, primary reason for ICU admission, the Informant Questionnaire on Cognitive Decline in the Elderly score (30), a history of moderate alcohol use (≥ 2 drinks per day) or depression (as evidenced by antidepressant use at the time of admission), the Pre-Deliric Delirium Risk Score (31), the use of continuous IV sedation and opioid therapy, and the baseline SAS and ICDSC scores. The SAS was used to evaluate level of sedation every 4 hours with a SAS score of at least 5 representing agitation (26) .
The QTc interval was measured by the bedside nurse every 6 hours using the bedside monitor. If an observed episode of potential QTc-interval prolongation (≥ 500 ms or ≥ 60 ms above baseline) was confirmed by a 12-lead electrocardiogram, then the patient was excluded from the study unless the patient was concomitantly receiving a nonstudy medication with the potential to prolong the QTc interval (32, 33) . In this scenario, if the ICU team felt that this medication could be discontinued, the study medication was continued for a further 12 hours and only discontinued if the QTc interval remained prolonged. Signs of extrapyramidal symptoms (EPSs) were monitored twice daily. If EPS were felt to be present, the subject was examined by an attending neurologist, who in consultation with the ICU team decided whether study removal was warranted. When the subject was deemed to be excessively sedated by the ICU team and receiving a sedating medication, the sedating medication was held (or decreased) until the subject reached the team's desired wakefulness goal. In situations where excessive sedation persisted after study drug administration, and the subject was not receiving another sedating medication, the subject was removed from the study. Blood pressure was monitored 30 minutes after each study dose. Subjects with persistent hypotension (systolic blood pressure ≤ 90 mm Hg) despite adequate fluid resuscitation in whom the ICU team felt that haloperidol was the primary causative factor were removed from the study. All subject-initiated episodes of device removal were documented. The primary study outcome was the incidence of delirium that developed during the period of study drug administration. Secondary delirium-related outcomes included the incidence of delirium that developed during ICU admission, the time to delirium occurrence, the proportion of 12-hour ICU shifts without delirium, and among those subjects who developed delirium, the duration of delirium until if first resolved for at least 12 hours. Other secondary efficacy outcomes included the hours per study day spent agitated, the proportion of 12-hour ICU shifts without coma and without either coma or delirium, and among study days a continuous sedative was administered, the proportion of days DA protocol criteria was met and DA was completed, subjects ever receiving early mobilization, use of dexmedetomidine or nonstudy antipsychotic therapy, days of mechanical ventilation, duration of both ICU and hospital stay, and both ICU and hospital death. The disposition of subjects after hospital discharge was categorized into one of four groups: home, rehabilitation facility, chronic care facility, and death.
Data analysis
Given the absence of a published controlled study evaluating the efficacy of antipsychotic therapy for the prevention of delirium in critically ill adult at the time this study was designed, we relied on an unpublished retrospective analysis of 72 consecutive ICU patients from our institution who developed subsyndromal delirium. Among patients exposed to at least 24 hours of haloperidol therapy during the period of subsyndromal delirium, two of 16 patients (13%) developed delirium, whereas 24 of 56 patients (43%) not exposed to haloperidol developed delirium. Accordingly, we estimated using a 2-sided α level of 0.05 that we would need to enroll 34 subjects in each group to achieve 80% power to find a difference in the progression to delirium of at least 10%.
Data were analyzed using an intention-to-treat principle. Outcomes were compared using the Mann-Whitney U test (expressed as median and interquartile range [IQR]) or the chi-square test. Fisher exact tests were used for categorical data with rare events. For outcomes reported as a percentage of the time study drug was administered, a percentage was first calculated for each subject and then the median (IQR) was reported for each group. To further explore the timing of delirium onset, Cox regression analysis was used to model time to delirium onset, and the hazard ratio of treatment with haloperidol versus placebo was computed together with its 95% CI. Should a subject die in the ICU without developing delirium, sensitivity analyses were done by assigning these cases "worst case" outcomes and "best case" outcomes and redoing each of the analyses to test each hypothesis to see if the study conclusions would change. A p value of up to 0.05 was considered significant for all analyses. All statistical analyses were performed using Statistical Analysis Solutions version 9.4 (SAS, Cary, NC). (Fig. 1) . Among the 481 patients with subsyndromal delirium (35.4%) deemed eligible, 413 (85.9%) were excluded leaving 68 subjects to be randomized. No subjects withdrew from the study, and thus, 68 subjects were included in the final analysis. Baseline characteristics were not statistically different between the two study groups ( Table 2) . Subjects were primarily medical, were frequently admitted with sepsis or acute respiratory distress Table 2 ). For 18 of the 19 subjects who developed delirium, the bedside nurse, study investigator, and study psychiatrist were in full agreement that delirium was present. For one subject in the haloperidol arm, shortly after the bedside nurse and study investigator each deemed delirium to be present and before the psychiatrist could conduct his assessment, the patient experienced an acute hypoxic event and subsequently required deep sedation to manage mechanical ventilatory support. The patient subsequently died of a cardiac arrest 12 hours later that was not felt to be related to study participation.
RESUlTS
Use of haloperidol (vs placebo) also did not affect the proportion of subjects who developed delirium during the ICU admission (35.3 vs 26.5%; p = 0.43) ( Table 3) . Among the subjects who developed delirium, the time to the first occurrence of delirium (p = 0.22) (Fig. 2) and the median (IQR) days of delirium before it first resolved was similar between the haloperidol (2 [2] [3] ) and placebo (3 [2-4] ) groups (p = 0.26). Subjects having delirium on each study day are presented in Figure 3 . Haloperidol-treated subjects spent less (median [IQR]) hours per day agitated (0 [0-2] vs 2 [1] [2] [3] [4] [5] [6] ; p = 0.008). However, use of haloperidol (vs placebo) did not affect the median (IQR) proportion (%) of 12-hour nursing shifts that subjects were coma free (100 [87-100] vs 100 [91-100]; p = 0.71) or both coma and delirium free (91 [67-100] vs 94 [80-100]; p = 0.36). Use of haloperidol did not influence days spent on mechanical ventilation (p = 0.79) or in the ICU (p = 0.66) nor either ICU (p = 0.29) or hospital (p = 0.40) disposition ( Table 4) .
The proportion of subjects experiencing an unexpected (i.e., nonprotocolized) serious adverse event was similar (2.9% [haloperidol] vs 8.8%; p = 0.3). None of these serious adverse events were felt by the investigative team to be related to study drug administration. Only one study subject (in the placebo group) self-extubated and required reintubation. The proportion of subjects where study medication was discontinued because of a protocolized haloperidol-associated safety concern was not different between the haloperidol and placebo (20.6% vs 5.9; p = 0.15) groups ( Table 5 ).
DISCUSSION
Our investigation, the first randomized, double-blind, placebo-controlled trial to evaluate the prophylactic use of lowdose haloperidol in mechanically ventilated, critically ill adults, suggests that the early initiation of scheduled, low-dose haloperidol does not prevent delirium among patients with subsyndromal delirium and who are at high risk for developing delirium, and may in fact lead to greater delirium. Use of haloperidol failed to reduce the time to first delirium, duration of delirium, or the hours spent with delirium during the ICU stay. Although the number of hours patients spent agitated in the ICU was reduced, the clinical significance of this result remains unknown, given that haloperidol use was not associated with a change in the days that mechanical ventilation was required nor a change in either ICU or hospital disposition. Protocolized haloperidol-related safety concerns were four times greater in the patients exposed to haloperidol although this outcome was not a primary endpoint of the study.
Although being a single-center pilot study, our investigation has many strengths. Clinicians, investigators, patients, and their families remained blinded to treatment allocation. The use of randomization allowed the two patient groups to be well-matched. Medical, surgical, and trauma patients were all enrolled, and with study screening starting on the first ICU admission day, randomization occurred an average of 1 day after ICU admission. The study center had extensive experience using the SAS and the ICDSC (5, (23) (24) (25) (26) . The use of a well-established DA-SBT protocol allowed each patient to be evaluated for delirium when maximally awake, and a psychiatrist with extensive ICU experience confirmed the presence of all delirium (22) . No study patient received offstudy antipsychotic therapy during the study, and the method by which common haloperidol-related adverse effects were monitored and managed was protocolized a priori.
The results of our investigation differ from controlled studies, where the administration of low-dose antipsychotic therapy to surgical patients has been shown to reduce delirium prevalence, delay its occurrence, and/or shorten its duration (10) (11) (12) (13) (14) (15) (16) . Although some of the patients in these investigations required short-term, postoperative ICU care (14) (15) (16) , very few would be considered to be deemed to be critically ill. Risk factors for delirium that are different between elective surgery patients and the critically ill may help explain the lack of benefit we observed with the use of haloperidol (17, 18, 33) . Critically ill patients may be at greater risk for experiencing haloperidolassociated adverse effects (20, 21, 34) . Given the frequency of adverse effects necessitating haloperidol discontinuation that were observed and the fact that monitoring for adverse effects is less stringent in routine ICU practice, haloperidol use to prevent delirium in critically ill patients with subsyndromal delirium is difficult to justify. Until results from larger, prospective controlled studies either confirm or refute our findings, clinicians should follow recommendations from the recent SCCM pain, agitation, and delirium guidelines and avoid using antipsychotics to prevent delirium (6) .
Instead, critical care clinicians should focus on delirium risk factor reduction and early patient mobilization (6) (7) (8) (35) (36) (37) (38) .
Limitations of our study must also be acknowledged. Our pilot investigation may have been too small to detect a difference in delirium with the use of haloperidol if one exists. The fact that the absolute difference in delirium incidence was almost 13% greater in the haloperidol group suggests that a benefit with haloperidol use, if one truly exists, is likely small or that the incidence of delirium is higher. The rigorous study criteria we chose, although common among studies evaluating pharmacologic delirium prevention and treatment strategies in the critically ill, led to only 14% of patients with subsyndromal delirium actually being enrolled and thus the external validity of our study may be limited (20, 21, 25) . There may be patients excluded from our study (e.g., not requiring mechanical ventilation or older than 85 yr) who might have benefited from haloperidol therapy.
The high proportion of patients receiving continuous IV sedation may have led to a greater proportion of patients being deemed to have subsyndromal delirium and thus potentially eligible for study enrollment. The use of strategies known to affect ICU delirium occurrence, although not protocolized for the purposes of the study, was similar between the two groups. While compliance with a well-established DA-SBT protocol was high, early mobilization was in place in only one of the three ICU studies (7) . Randomization, in this medical ICU, was similar between haloperidol (n = 15) and placebo (n = 16) groups. The results from our single-center study might be different from that which could be observed at a center with a different patient mix or delirium prevention practices. Dexmedetomidine, although not shown to prevent delirium in the critically ill and administered to fewer than 15% of subjects, may have affected the rate of delirium reported (39, 40) . Although patients were randomized an average of 24 hours after ICU admission, the initiation of haloperidol at the onset of critical illness may have led to a different result. Use of a higher dose of haloperidol may have also led to different results. Finally, we cannot exclude that surgical critically ill patients with subsyndromal delirium may not benefit from haloperidol, given that they represented less than one third of the total subjects (15) .
The role for haloperidol and other antipsychotics to prevent delirium in critically ill adults needs to be studied in large studies that have power to measure differences in an outcome like mortality (41) . Future investigations should also evaluate the role of treating subsyndromal delirium in the ICU with antipsychotic therapy on post-ICU outcomes, such as posttraumatic stress disorder, depression, long-term cognition, sleep quality, and functionality (42, 43) . The agitation-sparing effect of haloperidol requires further investigation (21) . In conclusion, this double-blind, randomized pilot study suggests that other than a reduction in agitation, the administration of lowdose IV haloperidol in critically ill adults with subsyndromal delirium may not prevent delirium occurrence and is associated with potential safety concerns. Hypotension, % (n) 2.9 (1) 2.9 (1) 1.00
